Esperion Therapeutics

From Wikipedia, the free encyclopedia
Esperion Therapeutics, Inc.
TypePublic
Nasdaq: ESPR
Russell 2000 Component
IndustryPharmaceutical
Founded2008 (2008)
Founder
  • Dr. Roger Newton
HeadquartersAnn Arbor, Michigan
Key people
Timothy M. Mayleben (president and CEO)
  • Decrease(US$26.1 million) (2013)
  • Decrease(US$11.7 million) (2012)
Total assets
  • IncreaseUS$78.3 million (2013)
  • US$7.31 million (2012)
WebsiteEsperion.com
Footnotes / references
financial information[1]:F-3, 4

Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

History[]

Pfizer acquired the original Esperion in 2004 for US$1,300,000,000 as a defensive move to prevent ETC-216 from falling into competitors' hands.[2]:165 Two years later, in 2006, Pfizer decided to kill the Esperion organization and development of ETC-216. In May 2008, Dr. Roger Newton, Esperion's founder and chief scientific officer, raised sufficient capital to acquire rights to ETC-1002 and Esperion from Pfizer, thereby leading to a second independent period for the company.[2]:165[3][4] In June 2013, Esperion became a public company again through an initial public offering.[5] As of April 2014, Esperion was traded on NASDAQ under the symbol "ESPR".[6]

Products[]

The company's main products are NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid), the first approved oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering combination medicine that is now available in U.S. pharmacies.

References[]

  1. ^ "Esperion Therapeutics, Inc". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 13, 2014. Commission File Number:001-35986.
  2. ^ Jump up to: a b Li, Jie Jack (2009). Triumph of the Heart: The Story of Statins. Oxford University Press. ISBN 9780195323573.
  3. ^ "History". Esperion Therapeutics. Archived from the original on April 29, 2012.
  4. ^ Catherine Shaffer (2008). "Pfizer jettisons Esperion". Nat. Biotechnol. 26 (7): 724–725. doi:10.1038/nbt0708-724. PMID 18612282. S2CID 205269230.closed access
  5. ^ Huggett, Brady (December 2013). "Burning Bright". Nat. Biotechnol. 31 (12). pp. 1068–71.open access
  6. ^ "ESPR stock quote". NASDAQ. Retrieved April 22, 2014.

Further reading[]

Retrieved from ""